West Pharmaceutical
573 hedge funds and large institutions have $18.8B invested in West Pharmaceutical in 2020 Q3 according to their latest regulatory filings, with 101 funds opening new positions, 199 increasing their positions, 210 reducing their positions, and 48 closing their positions.
191% more call options, than puts
Call options by funds: $20M | Put options by funds: $6.87M
110% more first-time investments, than exits
New positions opened: 101 | Existing positions closed: 48
19% more capital invested
Capital invested by funds: $15.8B → $18.8B (+$2.98B)
10% more funds holding
Funds holding: 523 → 573 (+50)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
5% less repeat investments, than reductions
Existing positions increased: 199 | Existing positions reduced: 210
1.26% less ownership
Funds ownership: 94.11% → 92.85% (-1.3%)
Top Buyers
| 1 |
Invesco
Atlanta,
Georgia
|
+$123M |
| 2 |
Goldman Sachs
New York
|
+$114M |
| 3 |
BlackRock
New York
|
+$70.7M |
| 4 |
APG Asset Management
Amsterdam,
Netherlands
|
+$68.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$58.8M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$223M |
| 2 |
JP Morgan Chase
New York
|
-$119M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$55.3M |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
-$54.6M |
| 5 |
WCM Investment Management
Laguna Beach,
California
|
-$49.4M |
WST Hedge Fund Activity: Q3 2020 in Review
573 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q3 2020, worth a combined $18.8B — up 19% from $15.8B a quarter earlier.
Buyers outnumbered sellers: 101 funds opened new WST positions and 48 closed out — a net gain of 53 holders — while 199 added to existing stakes and 210 trimmed.
The largest buyer was Invesco, adding an estimated $123M. The largest seller was T. Rowe Price Associates, cutting an estimated $223M.
- 573 institutional investors held West Pharmaceutical (WST) as of Q3 2020, up from 523 in Q2 2020.
- Funds reported $18.8B of West Pharmaceutical stock for Q3 2020, up 19% quarter-over-quarter.
- 101 funds opened new West Pharmaceutical positions in Q3 2020 and 48 closed out, a net change of +53 holders.
- The largest West Pharmaceutical buyer in Q3 2020 was Invesco, an estimated $123M added.
- The largest West Pharmaceutical seller in Q3 2020 was T. Rowe Price Associates, an estimated $223M sold.
Based on aggregated 13F filings for Q3 2020.